anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a medical image processing apparatus that can receive medical image data at each unit in conformity with the state of the transmission of data at each medical image generator.  <P>SOLUTION: A CPU 10 stores a timeout time at each reception channel which is set by an input unit 20 operated by a user in a timeout management table 73. Whenever receiving the medical image data, the CPU 10 updates the last receiving time received which is associated with the reception channel with a current time 62. Subsequently, the CPU 10 successively determines whether the difference between the last receiving time and the current time exceeds the timeout time. When it is determined that the difference has exceeded the timeout time, it is determined that the medical image data for one examination have been received at the reception channel which is determined to have exceeded the timeout time, and the CPU 10 stores the medical image data D3 which are stored in a reception standby list table 71 and associated with the reception channel in an image examination standby list table 72.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Application of the physical laws of energy and mass conservation at the whole-body level is not necessarily informative about causal mechanisms of weight gain and the development of obesity. The energy balance model (EBM) and the carbohydrate-insulin model (CIM) are two plausible theories, among several others, attempting to explain why obesity develops within an overall common physiological framework of regulation of human energy metabolism. These models have been used to explain the pathogenesis of obesity in individuals as well as the dramatic increases in the prevalence of obesity worldwide over the past half century. Here, we summarize outcomes of a recent workshop in Copenhagen that brought together obesity experts from around the world to discuss causal models of obesity pathogenesis. These discussions helped to operationally define commonly used terms; delineate the structure of each model, particularly focussing on areas of overlap and divergence; challenge ideas about the importance of purported causal factors for weight gain; and brainstorm on the key scientific questions that need to be answered. We hope that more experimental research in nutrition and other related fields, and more testing of the models and their predictions will pave the way and provide more answers about the pathogenesis of obesity than those currently available.
The invention relates to a nutriment supplement and a preparation method for the small dosage folic acid and vitamin B12. The folic acid cannot be synthesized by the human body, which must rely on the exogenetic supply. The folic acid has close relation with the vitamin B12 on the in vivo metabolism and the function. Although a plurality of preparations containing the folic acid are seld in the market, most of which are the preparation comprising the multivitamins, the calcium iron and other nutrient preparations or the sole preparation comprising the folic acid; the preparation only comprising the folic acid and the vitamin B12 contains the big dosage folic acid and the big dosage folic acid is not suitable for the pregnant women and the crowd lacking of folic acid. The invention is characterized in comprising the folic acid, the vitamin B12 and the medicine carrier according to the weight account matching 10 to 400: 1: 400 to 4000; the nutriment supplement is made into a capsule (tablet) comprising the folic acid 100 to 400 Mug, the vitamin B12 1 to 10 Mug according to the conventional method in the pharmaceutics. The invention has an advantage of capability for supplying the reasonable nutrition supplement to the people lacking of folic acid.
The invention discloses prinsepia utilis royle puree cosmetic and a preparation method and application thereof. The method for preparing prinsepia utilis royle puree includes steps of fermenting prinsepia utilis royle as base by brewer's yeast as strain. The prinsepia utilis royle puree prepared by this method also falls into the scope of this invention. The invention further discloses a product, and its active ingredient is the prinsepia utilis royle puree. The product has functions of (a) and/or (b) and/or (c), wherein (a) for oxidation resistance, (b) for capability of removing DPPH free radicals, and (c) for ageing resistance. By the fermenting technology, active substances can be extracted from prinsepia utilis royle, operation is simple and without any additives, the produced prinsepia utilis royle yeast, namely the prinsepia utilis royle puree, has no harm to skin. The product contains polysaccharide or flavone-rich matters, and fermenting ingredients in fermenting filtrate have synergetic action, and have excellent anti-oxidation and anti-ageing function.
Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
After induction of apoptosis, with hydrochloric Terazosine, acting on the elimination of the prostate tissue due to the preceded atrophy - marasmus due to Dutasteride or Finasteride, the most rapid in immediate/medium-term and long-term practice for reduction of prostate tissue may be promoted in comparison to the separate action of - N- or -Φ-. At the same time, our conclusion is revealed, crucially secure and self- evidenced that, resulting by this fact, the prostate cancer is promoted and achieved in actions and not words, thanks to the crucial elimination of time - and not only - margin for the development of malignancy either further evolution - as happens often - of an already existing hidden, which has not reached yet and will not reach the limit of 1/10 cells [or approximate time limit of 8-10 years old). Furthermore, elimination on time of dysplastic-metaplastic cells due to stimulation of production and, inevitably, destruction from P53, the protein of apoptosis that destructs selectively all cells that are not functioning well from morphological point of view. With Fenretinide, an explosive collaborative prevention, harmless to the prevention of cancer to special population groups mentioned in the description and the indications of our practice. The additions of Verapamile/Diltiazeme, within the frame of particularities of action and application field, distinguish in the annulment of MDR, the imprisonment of PgP170 and in fact save the population of patients we address to. TECHNIQUE LEVEL We know nothing respective to our entire methodological conclusion.
PURPOSE: A pharmaceutical composition containing Daphne genkwa extract, a fraction thereof, or a compound isolated from the same is provided to effectively enhance Th1 cytokine secretion and to prevent or treat atopic dermatitis. CONSTITUTION: A pharmaceutical composition for preventing or treating atopic dermatitis contains Daphne genkwa extract as an active ingredient. The extract is prepared from stems, roots, leaves, petals, or buds of Daphne genkwa using water, low carbon number alcohol of C1-C4, or acetone. The pharmaceutical composition also contains a Daphne genkwa fraction as an active ingredient. The fraction is prepared using hexane, chloroform, and ethyl acetate. The pharmaceutical composition contains a compound of chemical formula 1 as an active ingredient.
Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
This study sought to investigate if there was a significant difference between the Huntington's Disease gene expansion carriers who were impaired on the cognitive domains, social cognition and executive functions. Also, it was investigated which of the cognitive domains could predict the decrease in total functional capacity over a 6-year follow-up period. Premanifest and motor-manifest Huntington's Disease gene expansion carriers (N = 98), were examined with a neurological and neuropsychological examination at Time 1 (year 2012-2013). Regression-based normative data was used to classify impairments on the two cognitive domains. Follow-up participants (N = 80) had their functional capacity reexamined at Time 2 (year 2018-2020), to examine which cognitive domain could predict the decrease in functional capacity over the 6-year follow-up. More than 50% of the participants were impaired on the domain of social cognition. These participants were significantly different from the participants who were impaired on executive functions. The motor function and impairments on social cognition significantly predicted the decline in functional capacity. The Emotion Hexagon test was the only significant social cognitive task, that predicted the decline in functional capacity. Social cognition includes unique and separate functions in Huntington's Disease, unaffected by executive functions. This study emphasizes the importance of regular assessment of social cognition in Huntington's Disease and the clinical relevance of impaired social cognitive function.
Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks. Specific topics in emails include "positive self-talk", "daily relaxation breathing techniques", "better sleep", and "ways to find pleasure".
An immersed-in-wine Chinese medicine in the form of wine or pill for preventing and curing AIDS is disclosed. For the medical wine, it is prepared from 7 Chinese-medicinal materials including ginseng, white atractylodes rhizome, scutellaria root, raw liquorice root, etc. through immersing them in pure grains wine. For the medical capsules, it is prepared from 14 Chinese-medicinal materials including ginseng, bupleurum root, liquorice root, lucid ganoderma, etc. through immersing them in pure grains wine, filtering, adding honey and pilling. Its advantage is better curative effect.
FIELD: veterinary medicine. SUBSTANCE: method involves administering cow placenta extraction having specific bacteriophages to cows. The preparation is administered into the ischiorectal fossa region as injection into loose connective fat to a depth of 3-5 cm from two sides at a dose of 0.1 ml per 1 kg of animal body mass. The dose is divided into two parts, and the preparation is applied twice. The first injection is done directly after birth. The second one is done 8-12 h later after the first injection. EFFECT: enhanced quality of prophylaxis. 2 cl
Patients receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening.
The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle, especially for the muscular dystrophies.
BACKGROUND: Recessive GJB2 variants, the most common genetic cause of hearing loss, may contribute to progressive sensorineural hearing loss (SNHL). The aim of this study is to build a realistic predictive model for GJB2-related SNHL using machine learning to enable personalized medical planning for timely intervention.
METHOD: Patients with SNHL with confirmed biallelic GJB2 variants in a nationwide cohort between 2005 and 2022 were included. Different data preprocessing protocols and computational algorithms were combined to construct a prediction model. We randomly divided the dataset into training, validation, and test sets at a ratio of 72:8:20, and repeated this process ten times to obtain an average result. The performance of the models was evaluated using the mean absolute error (MAE), which refers to the discrepancy between the predicted and actual hearing thresholds.
RESULTS: We enrolled 449 patients with 2184 audiograms available for deep learning analysis. SNHL progression was identified in all models and was independent of age, sex, and genotype. The average hearing progression rate was 0.61 dB HL per year. The best MAE for linear regression, multilayer perceptron, long short-term memory, and attention model were 4.42, 4.38, 4.34, and 4.76 dB HL, respectively. The long short-term memory model performed best with an average MAE of 4.34 dB HL and acceptable accuracy for up to 4 years.
CONCLUSIONS: We have developed a prognostic model that uses machine learning to approximate realistic hearing progression in GJB2-related SNHL, allowing for the design of individualized medical plans, such as recommending the optimal follow-up interval for this population.
PCT No. PCT/JP96/01920 Sec. 371 Date Mar. 10, 1997 Sec. 102(e) Date Mar. 10, 1997 PCT Filed Jul. 10, 1996 PCT Pub. No. WO97/03130 PCT Pub. Date Jan. 30, 1997A crosslinkable polylactone-based composition comprising formulating 100 parts by weight of a polylactone (A) whose number average molecular weight is in the range of 10,000 to 300,000 and 0.1 to 30 parts by weight of a crosslinkable monomer (B) which can confine the molecular chain of the polylactone (A) by irradiating active energy radiation or by heating, a production method of a polylactone-based crosslinked molded article prepared by irradiating active energy radiation or by heating after melting and molding the above-mentioned crosslinkable polylactone-based composition at the temperature where crosslinking does not occur, and a polylactone-based crosslinked molded article obtained by the above method are offered. A cured polylactone-based molded article having similar properties is also obtained from the curable polylactone-based composition composed of a polylactone or polylactone composition (X) comprising a prescribed polylactone (C) and polyvalent alcohol (D), and a prescribed curing agent (Y). Since these molded articles obtained have biodegradability as well as excellent mechanical strength, thermal resistance, oil resistance, abrasion resistance, and shape-memorizable property which is a property to deform showing rubber elasticity on applying an external force when it is heated to soften and to tend to recover its initial shape of the molded article when it is reheated to soften, the product can be used for a sheet for fixing a patient in radiation therapy, a material for transcribing a shape of wig, a material for transcribing a shape of teeth, and gypsum.
A new class of poly(beta-amino alcohols) (PBAAs) has been prepared using combinatorial polymerization. The inventive PBAAs may be used in biotechnology and biomedical applications as coatings (such as coatings of films or multilayer films for medical devices or implants), additives, materials, excipients, non-biofouling agents, micropatterning agents, and cellular encapsulation agents. When used as surface coatings, these PBAAs elicited different levels of inflammation, both in vitro and in vivo, depending on their chemical structures. The large chemical diversity of this class of materials allowed us to identify polymer coatings that inhibit macrophage activation in vitro. Furthermore, these coatings reduce the recruitment of inflammatory cells, and reduce fibrosis, following the subcutaneous implantation of carboxylated polystyrene microparticles. These polymers may be used to form polyelectrolyte complex capsules for cell encapsulation. The invention may also have many other biological applications such as antimicrobial coatings, DNA or siRNA delivery, and stem cell tissue engineering.
INTRODUCTION: Clinical assessment in emergency departments (EDs) for possible acute myocardial infarction (AMI) requires at least one cardiac troponin (cTn) blood test. The turn-around time from blood draw to posting results in the clinical portal for central laboratory analysers is ~1-2 hours. New generation, high-sensitivity, point-of-care cardiac troponin I (POC-cTnI) assays use whole blood on a bedside (or near bedside) analyser that provides a rapid (8 min) result. This may expedite clinical decision-making and reduce length of stay. Our purpose is to determine if utilisation of a POC-cTnI testing reduces ED length of stay. We also aim to establish an optimised implementation process for the amended clinical pathway.
METHODS AND ANALYSIS: This quality improvement initiative has a pragmatic multihospital stepped-wedge cross-sectional cluster randomised design. Consecutive patients presenting to the ED with symptoms suggestive of possible AMI and having a cTn test will be included. Clusters (comprising one or two hospitals each) will change from their usual-care pathway to an amended pathway using POC-cTnI-the 'intervention'. The dates of change will be randomised. Changes occur at 1 month intervals, with a minimum 2 month 'run-in' period. The intervention pathway will use a POC-cTnI measurement as an alternate to the laboratory-based cTn measurement. Clinical decision-making steps and logic will otherwise remain unchanged. The POC-cTnI is the Siemens (Erlangen Germany) Atellica VTLi high-sensitivity cTnI assay. The primary outcome is ED length of stay. The safety outcome is cardiac death or AMI within 30 days for patients discharged directly from the ED.
ETHICS AND DISSEMINATION: Ethics approval has been granted by the New Zealand Southern Health and Disability Ethics Committee, reference 21/STH/9. Results will be published in a peer-reviewed journal. Lay and academic presentations will be made. Māori-specific results will be disseminated to Māori stakeholders.
TRIAL REGISTRATION NUMBER: ACTRN12619001189112.
The accumulation of amyloid-beta (Aβ) peptides is a crucial factor in the neuronal degeneration of Alzheimer's disease (AD). The current study investigated the underlying neuroprotective mechanisms of shrimp shell extract (SSE) and liposome-encapsulated SSE (SSE/L) against Aβ1-42-induced neuronal damage and death in rats. Intracerebroventricular infusion of Aβ1-42 effectively induced memory decline, as observed in a reduction of the rat's discriminating ability in the novel object recognition and novel object location tasks. Oral pretreatment with 100 mg/kg of SSE demonstrated no preventive effect on the memory decline induced by Aβ1-42 infusion. However, treatment with SSE/L 100 mg/kg BW effectively attenuated memory deficits in both behavioral assessments following two and four weeks after Aβ1-42 infusion. Moreover, SSE/L exerted neuroprotective effects by reducing lipid peroxidation and increasing Nrf2/HO-1 expression. There was a significant decrease in Iba1 and GFAP (biomarkers of microglia and astrocyte activity, respectively), as well as a decrease in the levels of NF-κB expression and the inflammatory cytokines TNF-α and IL-6 in the cortical and hippocampal tissues. Treatment with SSE/L also reduced the pro-apoptotic proteins Bax and cleaved caspase-3 while raising the anti-apoptotic protein Bcl2. In addition, the beneficial effects of SSE/L were along with the effects of a positive control commercial astaxanthin (AST). The findings of this study indicated that SSE/L provided neuroprotective effects on Aβ1-42-induced AD rats by ameliorating oxidative stress, neuroinflammation and apoptotic cell death. Therefore, SSE/L might be employed to prevent and mitigate Aβ accumulation-induced neurotoxicity in AD.
As with other drugs that antagonize dopamine D2 receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents.  
  
Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.  
  
Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. An increase in pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see Nonclinical Toxicology (13.1)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.
A composition includes particles including at least about 95 wt% of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 ??m to about 1.9 ??m. Another composition also includes particles including at least about 95 wt% of amphotericin B, wherein at least about 80 wt% of the particles have a geometric diameter ranging from about 1.1 ??m to about 1.9 gm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 ??m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.